PRMT Inhibition of Dipeptide Repeat Toxicity in ALS and FTD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The expansion of a hexanucleotide repeat in the C9ORF72 gene leads to the formation of dipeptide repeat proteins (DRPs) that cause cellular toxicity, particularly in neuronal cells, contributing to neurodegenerative diseases like ALS and FTD, with the mechanisms of action and contributions of each DRP to neurodegeneration unclear.
Innovation Solution
Administering Type I protein arginine methyltransferase (PRMT) inhibitors, such as MS023, MS049, EPZ020411, GSK715, and TP 064, to inhibit the asymmetric methylation of arginine substrates within DRPs, thereby reducing cellular toxicity, and optionally combining with agents like riluzole and edaravone or antibodies blocking CD40 and CD40L interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If Type I PRMT inhibitors are administered to inhibit asymmetric methylation of arginine substrates within DRPs, then cellular toxicity caused by DRPs is decreased, but the mechanism of action and contributions of each DRP to neurodegeneration remain unclear
Solution Approach 1:
The patent applies this principle by utilizing the toxic DRPs themselves as targets for inhibition. By administering Type I PRMT inhibitors that specifically target the asymmetric methylation of arginine substrates within DRPs, the harmful toxic effect is converted into a therapeutic benefit. The inhibitors transform the harmful methylation process into a controllable mechanism, reducing cellular toxicity while providing a clear mechanistic pathway for treatment.
2Reliability
If Type I PRMT inhibitors are used to abrogate toxicity produced by asymmetric methylation, then neuronal cells are protected from DRP toxicity, but the complexity of the treatment approach increases
Solution Approach 1:
The patent applies parameter changes by targeting the specific biochemical parameter of asymmetric methylation of arginine substrates within DRPs. The Type I PRMT inhibitors modify the methylation state of arginine residues, transforming the chemical parameter of the DRPs from toxic to non-toxic. This biochemical parameter change provides a precise and controllable mechanism for protecting neuronal cells without requiring complex multi-component treatment systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The methods effectively decrease cellular toxicity caused by DRPs, particularly in neuronal cells, offering potential treatments for ALS and FTD by mitigating the toxic effects of DRPs and protecting neuronal cells from degeneration.
Implementation Method 1
the toxic effects caused by DRPs is driven by asymmetric methylation of the arginine substrates within the dipeptide repeats, rather than by aberrant methylation of endogenous proteins
Data Source
AI summary
Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).